Sutro Biopharma PE Ratio 2017-2021 | STRO

Current and historical p/e ratio for Sutro Biopharma (STRO) from 2017 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Sutro Biopharma PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Sutro Biopharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 18.99 0.00
2021-06-30 18.59 $-1.82 0.00
2021-03-31 22.76 $-0.75 0.00
2020-12-31 21.71 $-0.93 0.00
2020-09-30 10.05 $-0.09 0.00
2020-06-30 7.76 $-1.10 0.00
2020-03-31 10.20 $-2.64 0.00
2019-12-31 11.00 $-2.42 0.00
2019-09-30 9.09 $-1.78 0.00
2019-06-30 11.38 $-22.48 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.876B $0.043B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00